These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 7004635)

  • 1. Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
    Irwin LE; Chlebowski RT; Weiner JM; Reynolds R; Pugh RP; Ryden VM; Bateman JR
    Cancer Treat Rep; 1980; 64(8-9):981-4. PubMed ID: 7004635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials].
    Jouve M; Palangie T; Belli L; Dorval T; Garcia-Giralt E; Beuzeboc P; Scholl S; Mosseri V; Livartowski A; Vedrenne J
    Bull Cancer; 1989; 76(6):643-52. PubMed ID: 2673438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of levamisole hydrochloride on advanced and recurrent breast cancer--LMS randomized controlled study of a group responding to CAF (cyclophosphamide, adriamycin, and 5-FU) therapy].
    Taguchi T; Izuo M; Ogawa N; Hayasaka H; Akai S; Tazima S; Fujii G; Tominaga T; Okamoto T; Kubo K; Yoshida M; Ota K; Sakai K; Hattori T; Inoue G; Nomura Y
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1595-608. PubMed ID: 6764119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
    Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
    de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
    Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
    Abeloff MD; Ettinger DS
    Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey D; Gelman R; Falkson G
    Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
    Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
    Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
    Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy in advanced breast cancer. A report of the Working Party of the Multicentre Cancer Chemotherapy Group.
    Spittle MF; Bates TD; Kitchen G; Nicol NT; Wheeler T; Edelstyn G; MacRae KD; Ostrowski MJ
    Clin Oncol; 1980 Jun; 6(2):153-7. PubMed ID: 7408282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.